Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Dociparstat sodium - Cantex Pharmaceuticals

Alternative Names: CX-01; DSTAT; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 19 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals; Chimerix
  • Class Anti-inflammatories; Anticoagulants; Antineoplastics; Heparins; Ischaemic heart disorder therapies; Polysaccharides
  • Mechanism of Action Cathepsin G inhibitors; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors; Platelet factor 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Acute myeloid leukaemia; Blood coagulation disorders; Brain injuries; Chronic obstructive pulmonary disease; Lung cancer; Myelodysplastic syndromes; Myocardial infarction; Pancreatic cancer; Reperfusion injury; Solid tumours; Thrombocytopenia

Most Recent Events

  • 12 Jul 2022 Chimerix terminates the license and development agreement with Cantex for dociparstat sodium
  • 16 May 2022 Chimerix terminates phase III DASH-AML trial in Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (IV, Infusion) due to slow recruitment (NCT04571645)
  • 31 Dec 2021 Chimerix has several US and foreign issued patents and pending US and foreign applications for Dociparstat sodium in USA prior to December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.